Literature DB >> 33131315

Long-Term Blood Pressure Variability and Risk of Cardiovascular Disease Events Among Community-Dwelling Elderly.

Michael E Ernst1, Enayet K Chowdhury2,3, Lawrence J Beilin4, Karen L Margolis5, Mark R Nelson6, Rory Wolfe2, Andrew M Tonkin2, Joanne Ryan2, Robyn L Woods2, John J McNeil2, Christopher M Reid2,3.   

Abstract

High office blood pressure variability (OBPV) in midlife increases the risk of cardiovascular disease (CVD), but the impact of OBPV in older adults without previous CVD is unknown. We conducted a post hoc analysis of ASPREE trial (Aspirin in Reducing Events in the Elderly) participants aged 70-years and older (65 for US minorities) without history of CVD events at baseline, to examine risk of incident CVD associated with long-term, visit-to-visit OBPV. CVD was a prespecified, adjudicated secondary end point in ASPREE. We estimated OBPV using within-individual SD of mean systolic BP from baseline and first 2 annual visits. Cox proportional hazards regression was used to calculate hazard ratios (HR) and 95% CI for associations with CVD events. In 16 475 participants who survived to year 2 without events, those in the highest tertile of OBPV had increased risk of CVD events after adjustment for multiple covariates, when compared with participants in the lowest tertile (HR, 1.36 [95% CI, 1.08-1.70]; P=0.01). Similar increased risk was observed for ischemic stroke (HR, 1.56 [95% CI, 1.04-2.33]; P=0.03), heart failure hospitalization, or death (HR, 1.73 [95% CI, 1.07-2.79]; P=0.02), and all-cause mortality (HR, 1.27 [95% CI, 1.04-1.54]; P=0.02). Findings were consistent when stratifying participants by use of antihypertensive drugs, while sensitivity analyses suggested the increased risk was especially for individuals whose BP was uncontrolled during the OBPV estimation period. Our findings support increased OBPV as a risk factor for CVD events in healthy older adults with, or without hypertension, who have not had such events previously. Registration- URL: https://www.clinicaltrials.gov; Unique identifiers: NCT01038583; URL: https://www.isrctn.com; Unique identifiers: ISRCTN83772183.

Entities:  

Keywords:  blood pressure; cardiovascular disease; hypertension; intrinsic factors; risk factors

Year:  2020        PMID: 33131315      PMCID: PMC7666049          DOI: 10.1161/HYPERTENSIONAHA.120.16209

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  23 in total

1.  Visit-to-Visit Blood Pressure Variability, Coronary Atheroma Progression, and Clinical Outcomes.

Authors:  Donald Clark; Stephen J Nicholls; Julie St John; Mohamed B Elshazly; Haitham M Ahmed; Haitham Khraishah; Steven E Nissen; Rishi Puri
Journal:  JAMA Cardiol       Date:  2019-05-01       Impact factor: 14.676

2.  Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.

Authors: 
Journal:  Contemp Clin Trials       Date:  2013-10-07       Impact factor: 2.226

3.  Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies.

Authors:  Jung-Sun Kim; Sungha Park; Ping Yan; Barrett W Jeffers; César Cerezo
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2017-04-01

4.  Systolic blood pressure variability is an important predictor of cardiovascular outcomes in elderly hypertensive patients.

Authors:  Enayet K Chowdhury; Alice Owen; Henry Krum; Lindon M H Wing; Mark R Nelson; Christopher M Reid
Journal:  J Hypertens       Date:  2014-03       Impact factor: 4.844

5.  Associations of aortic distensibility and arterial elasticity with long-term visit-to-visit blood pressure variability: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Daichi Shimbo; Steven Shea; Robyn L McClelland; Anthony J Viera; Devin Mann; Jonathan Newman; Joao Lima; Joseph F Polak; Bruce M Psaty; Paul Muntner
Journal:  Am J Hypertens       Date:  2013-03-28       Impact factor: 2.689

6.  Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial).

Authors:  Tara I Chang; David M Reboussin; Glenn M Chertow; Alfred K Cheung; William C Cushman; William J Kostis; Gianfranco Parati; Dominic Raj; Erik Riessen; Brian Shapiro; George S Stergiou; Raymond R Townsend; Konstantinos Tsioufis; Paul K Whelton; Jeffrey Whittle; Jackson T Wright; Vasilios Papademetriou
Journal:  Hypertension       Date:  2017-07-31       Impact factor: 10.190

7.  The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Authors:  Ian M Kronish; Amy I Lynch; Suzanne Oparil; Jeff Whittle; Barry R Davis; Lara M Simpson; Marie Krousel-Wood; William C Cushman; Tara I Chang; Paul Muntner
Journal:  Hypertension       Date:  2016-05-23       Impact factor: 10.190

8.  Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.

Authors:  John J McNeil; Rory Wolfe; Robyn L Woods; Andrew M Tonkin; Geoffrey A Donnan; Mark R Nelson; Christopher M Reid; Jessica E Lockery; Brenda Kirpach; Elsdon Storey; Raj C Shah; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Michael Jelinek; Mobin Malik; Charles B Eaton; Donna Brauer; Geoff Cloud; Erica M Wood; Suzanne E Mahady; Suzanne Satterfield; Richard Grimm; Anne M Murray
Journal:  N Engl J Med       Date:  2018-09-16       Impact factor: 91.245

9.  Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension.

Authors:  Peter M Rothwell; Sally C Howard; Eamon Dolan; Eoin O'Brien; Joanna E Dobson; Bjorn Dahlöf; Peter S Sever; Neil R Poulter
Journal:  Lancet       Date:  2010-03-13       Impact factor: 79.321

10.  Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Authors:  Paul Muntner; Emily B Levitan; Amy I Lynch; Lara M Simpson; Jeffrey Whittle; Barry R Davis; John B Kostis; Paul K Whelton; Suzanne Oparil
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-04-16       Impact factor: 3.738

View more
  4 in total

1.  Long-Term Blood Pressure Variability and Kidney Function in Participants of the ASPREE Trial.

Authors:  Michael E Ernst; Michelle A Fravel; Katherine L Webb; James B Wetmore; Rory Wolfe; Enayet Chowdhury; Christopher M Reid; Robyn L Woods; Lawrence Beilin; Karen L Margolis; Anne M Murray; Kevan R Polkinghorne
Journal:  Am J Hypertens       Date:  2022-02-01       Impact factor: 3.080

2.  Variation in Mean Arterial Pressure Increases Falls Risk in Elderly Physically Frail and Prefrail Individuals Treated With Antihypertensive Medication.

Authors:  Sultana Monira Hussain; Michael E Ernst; Anna L Barker; Karen L Margolis; Christopher M Reid; Johannes T Neumann; Andrew M Tonkin; Thao Le Thi Phuong; Lawrence J Beilin; Thao Pham; Enayet K Chowdhury; Flavia M Cicuttini; Julia F M Gilmartin-Thomas; Prudence R Carr; John J McNeil
Journal:  Hypertension       Date:  2022-06-20       Impact factor: 9.897

3.  Long-Term Visit-to-Visit Mean Arterial Pressure Variability and the Risk of Heart Failure and All-Cause Mortality.

Authors:  Menghui Liu; Xiaohong Chen; Shaozhao Zhang; Yifen Lin; Zhenyu Xiong; Xiangbin Zhong; Yue Guo; Xiuting Sun; Huimin Zhou; Xingfeng Xu; Lichun Wang; Xinxue Liao; Xiaodong Zhuang
Journal:  Front Cardiovasc Med       Date:  2021-06-04

4.  Application of ensemble machine learning algorithms on lifestyle factors and wearables for cardiovascular risk prediction.

Authors:  Weiting Huang; Tan Wei Ying; Woon Loong Calvin Chin; Lohendran Baskaran; Ong Eng Hock Marcus; Khung Keong Yeo; Ng See Kiong
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.